American Home Products Corporation and Aventis Pharma have renegotiated their licensing agreement for trimegestone, a modern progestational molecule originated by Aventis for hormone replacement therapy.
Under the new agreement, Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP, has exclusive development and worldwide marketing rights for trimegestone for all indications and formulations except transdermal products.
The rights to combination use for hormone replacement therapy (HRT) with Premarin (conjugated estrogens tablets, USP) the world’s leading hormone replacement product marketed by Wyeth-Ayerst for nearly 60 years, are included in the agreement.
In addition, Wyeth-Ayerst will take full responsibility for development and marketing of combinations of trimegestone with 17 beta estradiol for hormone replacement therapy.
Aventis Pharma received a fee upon closing of the new agreement and will receive milestone payments for marketing authorizations obtained in major markets.
Under an exclusive supply agreement, Aventis Pharma will also act as Wyeth-Ayerst’s sole source for the active ingredient required for the manufacture of trimegestone through the year 2010.
Further financial details are not being disclosed.
“As a world leader in hormone replacement therapies, Wyeth-Ayerst is uniquely positioned to maximize the commercial potential of trimegestone. This agreement will provide Aventis Pharma with an attractive stream of revenue from trimegestone, while at the same time allowing us to focus our resources on products in other therapeutic areas where Aventis Pharma has a strategic advantage,” said Richard J. Markham, CEO of Aventis Pharma.
Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, is a major research-oriented pharmaceutical company with leading products in the areas of women’s health care, cardiovascular therapies, central nervous system drugs, anti- inflammatory agents, infectious disease, haemophilia, oncology, vaccines, and generic pharmaceuticals.
Aventis S.A. is one of the world’s leading life science companies, focused on two core business areas, pharmaceuticals and agriculture.